Constipation is one of those conditions that almost everyone experiences at some point, which is precisely why it tends to get dismissed. Drink more water. Eat more fiber. Exercise. These suggestions are not wrong for the general population, but for the roughly 15 percent of adults who deal with chronic constipation, they are often incomplete and sometimes counterproductive. Chronic constipation is not a single problem with a single solution. It is at least three different conditions wearing the same label, and figuring out which one you have changes the treatment completely. The fact that most people with chronic constipation never get subtyped is one of the bigger gaps in routine GI care.
How common is chronic constipation?
A systematic review and meta-analysis by Suares and Ford (2011) estimated the global prevalence of chronic constipation at approximately 14 percent, with significant regional variation. Women are affected roughly twice as often as men, and prevalence increases with age, particularly after age 65. In the United States alone, constipation accounts for over 2.5 million physician visits per year and is a leading reason for gastroenterology referral.
But prevalence numbers only tell part of the story. Many people with chronic constipation never seek medical attention, either because they do not consider it a 'real' medical problem, because they are embarrassed, or because they have been told to just eat more fiber and given up on getting actual help. The condition has a substantial quality-of-life impact that is often underappreciated. Studies comparing quality of life in chronic constipation patients to those with other chronic conditions have found impact levels comparable to conditions like diabetes, depression, and musculoskeletal disorders (Wald et al., 2007).
The three subtypes: why they matter
The most important concept in understanding chronic constipation is that it is not monolithic. Gastroenterologists and motility specialists recognize at least three distinct subtypes, each with different underlying mechanisms and different optimal treatments.
Normal-transit constipation is the most common subtype, accounting for roughly 60 percent of patients with chronic constipation. These patients have normal colonic transit on testing, meaning stool moves through the colon at a normal rate. Their symptoms typically involve perceived difficulty with evacuation, hard stools, or a feeling of incomplete emptying, despite objectively normal transit. The mechanism is thought to involve heightened visceral perception, meaning normal colonic activity is perceived as constipation. This subtype generally responds well to fiber supplementation (particularly psyllium), osmotic laxatives, and dietary modification.
Slow-transit constipation (STC) affects roughly 15 to 20 percent of patients with chronic constipation. In STC, the colon genuinely moves material more slowly than normal. This can be documented with a colonic transit study, either using radiopaque markers (Sitzmarks study), a wireless motility capsule, or scintigraphy. Patients with STC often report infrequent bowel movements (sometimes going a week or more), reduced or absent urge to defecate, and bloating. STC has been associated with reduced numbers of interstitial cells of Cajal in the colon and decreased levels of the neurotransmitter substance P, both of which contribute to impaired propulsive contractions (Knowles and Farrugia, 2011).
Defecatory disorders, also called outlet obstruction or pelvic floor dysfunction, account for roughly 25 to 40 percent of patients referred to specialist centers for refractory constipation (Rao et al., 2004). The most common variant is dyssynergic defecation, where the muscles of the pelvic floor contract when they should relax during a bowel movement, or fail to generate adequate propulsive force. The result is straining, incomplete evacuation, and a sensation of blockage. This is not a structural problem in most cases. It is a coordination problem, and it is remarkably treatable once identified.
âšī¸Think of the three subtypes this way: in normal-transit constipation, the equipment works but the perception is off. In slow-transit constipation, the colon itself is underperforming. In dyssynergic defecation, the exit mechanism is not coordinating properly. Each requires a different approach.
Why fiber fails for many people
The recommendation to eat more fiber is so deeply embedded in medical culture that questioning it feels almost heretical. And for normal-transit constipation, it is reasonable advice. Psyllium (a soluble, gel-forming fiber) in particular has good evidence for improving stool frequency and consistency in this population. A randomized trial by Bijkerk et al. (2004) found psyllium superior to bran for improving symptoms in chronic constipation.
But fiber does not work for everyone, and for some patients it makes things meaningfully worse. In slow-transit constipation, adding fiber to a colon that is already struggling to move material forward can increase bloating, distension, and discomfort without improving stool frequency. A study by Voderholzer et al. (1997) found that patients with slow transit had a poor response to fiber therapy, while those with normal transit or mild outlet dysfunction responded better. Insoluble fiber (wheat bran, for example) tends to be worse than soluble fiber in this context because it adds bulk without the gel-forming properties that facilitate transit.
For dyssynergic defecation, fiber may marginally improve stool consistency but does not address the core problem, which is the inability to coordinate the muscles involved in evacuation. Patients with dyssynergia who are told to simply eat more fiber often become frustrated as the advice fails to produce results, and this frustration can delay the diagnosis that would lead to effective treatment.
Diagnosing the subtype: what tests are available?
Subtyping constipation requires going beyond the standard colonoscopy. A colonoscopy is important for ruling out structural causes (masses, strictures, obstruction) but tells you nothing about how well the colon is functioning or whether the pelvic floor is coordinating properly. The key diagnostic tests are as follows.
- Colonic transit study. The most common method uses radiopaque markers (Sitzmarks). You swallow a capsule containing 24 small markers on day 1, and an abdominal X-ray on day 5 counts how many remain. Retention of more than 5 markers at day 5 suggests slow transit. The wireless motility capsule (SmartPill) is a more comprehensive alternative that also measures gastric and small bowel transit.
- Anorectal manometry. This test measures the pressures generated by the anal sphincter muscles and the rectum during squeezing, relaxing, and simulated defecation. It can identify dyssynergic patterns where the sphincter contracts instead of relaxing when the patient pushes.
- Balloon expulsion test. A small balloon is inflated in the rectum, and the patient is asked to expel it (usually within 1 to 3 minutes). Inability to expel the balloon is a simple, low-tech indicator of a defecatory disorder. It is often performed alongside anorectal manometry.
- Defecography (or MR defecography). This imaging study visualizes the pelvic floor anatomy and function during actual defecation. It can identify structural issues like rectoceles, intussusception, or excessive pelvic floor descent that contribute to outlet obstruction.
Not every patient with chronic constipation needs all of these tests. But if standard treatments (fiber, osmotic laxatives) have failed, pursuing at least anorectal manometry and a balloon expulsion test is a reasonable next step. Dyssynergic defecation is underdiagnosed precisely because these tests are not ordered often enough.
Biofeedback for dyssynergic defecation: the evidence
Biofeedback therapy for dyssynergic defecation is one of the great underappreciated success stories in gastroenterology. It is a specialized form of pelvic floor retraining where sensors provide visual or auditory feedback during simulated defecation, teaching the patient to relax the pelvic floor muscles and coordinate abdominal pushing. Sessions typically take place over 4 to 6 visits with a trained therapist.
A landmark randomized controlled trial by Rao et al. (2007) compared biofeedback to standard therapy (diet, exercise, and laxatives) and to sham biofeedback in patients with dyssynergic defecation. Biofeedback produced significant improvement in 79 percent of patients, compared to 22 percent with standard therapy. The improvements were sustained at 12-month follow-up. Subsequent studies have confirmed these findings, and biofeedback is now recommended as first-line therapy for dyssynergic defecation in ACG and AGA guidelines (Bharucha et al., 2013).
The challenge is access. Biofeedback therapy requires specialized equipment and trained therapists, and availability varies greatly by region. Many gastroenterologists are aware of the evidence but have difficulty referring patients because there is no local provider. Telehealth-guided biofeedback programs are beginning to emerge as a way to expand access, but they are still in early stages.
â ī¸If you have chronic constipation that has not responded to fiber, laxatives, or dietary changes, ask your gastroenterologist about anorectal manometry to check for dyssynergic defecation. If confirmed, biofeedback therapy has a success rate around 70 to 80 percent and is more effective than laxatives for this specific subtype.
What helps with tracking bowel patterns?
Chronic constipation management benefits significantly from detailed tracking because the subtype and treatment response are not always obvious from a single snapshot. Recording bowel movement frequency, stool consistency (using the Bristol Stool Scale), straining severity, sense of completeness, dietary fiber and fluid intake, and medication or supplement use creates a timeline that helps clinicians make better diagnostic and treatment decisions. An app like GLP1Gut can structure this daily logging so that patterns emerge over weeks rather than relying on imprecise recall at appointments.
Tracking is also valuable when trying new treatments. If you start an osmotic laxative or a secretagogue, documenting the response over 2 to 4 weeks gives you and your provider objective data about whether the treatment is working, partially working, or not helping at all.
Medications beyond fiber and basic laxatives
When first-line approaches fail, several prescription medications with good clinical trial evidence are available. Osmotic laxatives like polyethylene glycol (MiraLAX) remain a mainstay, with consistent evidence supporting their use for increasing stool frequency and improving consistency (Ford et al., 2014). Lactulose is an alternative osmotic agent, though it tends to cause more bloating.
Secretagogues represent a newer category that works by increasing fluid secretion into the intestinal lumen. Linaclotide (Linzess) and plecanatide (Trulance) are guanylate cyclase-C agonists that increase chloride and fluid secretion while also having analgesic effects on visceral pain. Lubiprostone (Amitiza) activates chloride channels to achieve a similar effect. All three have been shown to improve stool frequency, straining, and bloating in randomized controlled trials.
Prucalopride (Motegrity) is a highly selective serotonin 5-HT4 receptor agonist that stimulates colonic motility. It is particularly useful for slow-transit constipation, where the goal is to speed up a sluggish colon rather than just soften stools. Clinical trials demonstrated significant improvement in spontaneous complete bowel movements compared to placebo (Camilleri et al., 2008). Unlike older serotonin agonists (such as tegaserod, which was withdrawn for cardiac concerns), prucalopride has a cleaner cardiovascular safety profile.
How do I know if my constipation is chronic enough to need medical attention?
The Rome IV criteria define chronic constipation as having at least two of the following for at least 3 months with onset at least 6 months prior: straining more than 25 percent of the time, lumpy or hard stools more than 25 percent of the time, sensation of incomplete evacuation more than 25 percent of the time, sensation of anorectal blockage more than 25 percent of the time, manual maneuvers needed more than 25 percent of the time, or fewer than 3 spontaneous bowel movements per week. If you meet these criteria, a medical evaluation is appropriate.
Is it safe to use laxatives regularly?
Osmotic laxatives like polyethylene glycol can be used long-term without dependency. The old fear that laxatives 'make the bowel lazy' was based on outdated observations about stimulant laxatives used at high doses. Modern clinical guidelines support the regular use of osmotic laxatives and secretagogues for chronic constipation when needed. Stimulant laxatives (bisacodyl, senna) can also be used regularly in appropriate doses, though they may cause more cramping (Bharucha et al., 2013).
Can chronic constipation be caused by a pelvic floor problem?
Yes. Dyssynergic defecation, a type of pelvic floor dysfunction, is one of the most common causes of refractory constipation, affecting roughly 25 to 40 percent of patients referred to specialty centers. The pelvic floor muscles contract when they should relax during defecation, creating a functional obstruction. It is diagnosed with anorectal manometry and a balloon expulsion test, and biofeedback therapy is highly effective.